Compare Sana Biotechnology Inc (SANA) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs T Rowe Price Group Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while T Rowe Price Group Inc trades at $107.71 (market cap $23.34B). The key difference: T Rowe Price Group Inc is far larger — about 22.7× Sana Biotechnology Inc's market cap, and T Rowe Price Group Inc pays a 4.75% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TROW | |
|---|---|---|
Market Cap | $1.03B | $23.34B |
Sector | Health | Financials |
52-Week High | $5.92 | $121.68 |
52-Week Low | $2.68 | $86.19 |
Enterprise Value | $946.04M | $20.54B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal and key support at $109. The stock shows strong profitability with a net margin of 29.26% and ROE of 20.1%, supported by recent earnings beats in Q1 and Q2 2026. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and ongoing AI adoption, positioning the firm for growth amid equity outflows.
The outlook is mixed: valuation metrics like a P/E of 10.99 suggest potential upside to the $111.67 consensus target, but bearish technicals and analyst caution (63% hold rating) indicate near-term headwinds. Risks include market-sensitive revenue and competitive pressures, though dividend stability and institutional buying support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
